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Background: We sought to determine whether the extent of revascularization influenced clinical outcomes in patients undergoing high risk PCI 
(HRPCI) and whether Impella improved clinical outcomes when extensive revascularization was performed.
Methods: PROTECT II enrolled patients with 3-vessel disease and LVEF≤ 30% or with unprotected left main or last patent conduit and LVEF≤ 
35%. Pre-determined need for hemodynamic support was required and patients were randomized 1:1 to Impella or IABP with an aim for maximal 
revascularization in a single procedure. The 90-day outcome was a composite endpoint of 10 Major Adverse Events (MAE), including MACCE (death, 
myocardial infarction, stroke and any repeat revascularization). 413 patients with complete angiograms were included in the Intent to Treat (ITT) 
analysis. An Ischemia Zone Score (IZS) was developed to quantify the extent of revascularization, based on the anatomic impact of coronary 
stenoses > 50%. Scores were assigned (RCA: 2; LCX: 3; LAD: 6; Total: 11) with proximal lesions counting more than distal and branch lesions. The 
difference between the Pre and Post procedural IZS were used to define the extent of revascularization as “Limited” (change ≤2 IZS) or “Extensive” 
(change ≥3 IZS).
Results: Results from the ITT analysis are presented. Baseline characteristics were similar between the 2 groups: Age (67±11 years), Diabetes 
(51%), Class NYHA III/IV (57%), LVEF (24%±6%), Syntax score (30±13) and Pre-PCI IZS (9±2). The amount of revascularization was comparable 
between the 2 arms (4.4±2.8 for Impella vs. 4.7±2.7 for IABP, p=0.2). More extensive revascularization was associated with improved 90-day clinical 
outcomes. There was no difference in the 90-day MAE between Impella and IABP when limited revascularization was performed (59% vs 48%, p=0.2). 
However, when more extensive revascularization was performed, Impella improved outcomes compared to IABP (90 day MAE: 33% vs 48%, p=0.008, 
and 90 day MACCE 15% vs 28%p=0.007 respectively).
Conclusions: Percutaneous left ventricular assistance with Impella was associated with improved clinical outcomes compared to IABP when 
extensive revascularization was performed.
